June 20 2025
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Read more
June 20 2025
In REACH real-world analysis, a 23% risk reduction in A1C-adjusted three-point MACE was observed for Ozempic® (semaglutide) injection compared to dulaglutide
Read more
June 10 2025
Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Read more
Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.
We offer 797 job opportunities